Stock Screener App

Frei - Play StoreApp Store

Installieren Installieren

LENZ

$3.500.00%0.00

Lenz Therapeutics Inc (LENZ)

Date: O: H: L: C: Vol:

Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten

Form 4 LENZ Therapeutics Inc: Daniel R. Chevallard (CFO) For: 30 October - Investing.com Canada

Form 13D/A LENZ THERAPEUTICS For: 2 November By Investing.com - Investing.com Canada

Form 4 LENZ Therapeutics Inc: RA CAPITAL MANAGEMENT, L.P. (10% Owner) For: 29 October - Investing.com Canada

RA Capital Management sells $9.13M in Lenz Therapeutics shares By Investing.com - Investing.com UK

At $3.36 a share on average, RA Capital funds sell LENZ Therapeutics (LENZ) stock. - Stock Titan

LENZ Therapeutics, Inc. Stock 12‑Month Price Target Cut to $19.17, Implies 497% Upside - TradingView

Form 8K LENZ Therapeutics Inc For: 28 October By Investing.com - Investing.com Canada

Form 8K LENZ Therapeutics Inc For: 28 October By Investing.com - Investing.com UK

LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession - LENZ Therapeutics

Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Zacks Investment Research

Millennium Management Reveals 3.7% Stake in LENZ Therapeutics via Schedule 13G Amendment - Kalkine Media

LENZ Therapeutics (NasdaqGS:LENZ) Stock Forecast & Analyst Predictions - Simply Wall Street

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ - GlobeNewswire Inc.

LENZ Therapeutics, Inc. (LENZ) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Encourages LENZ Therapeutics, Inc. (LENZ) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating LENZ Therapeu - The National Law Review

A 5.7% stake in LENZ Therapeutics (LENZ) has been disclosed—but by whom? - Stock Titan

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against LENZ Therapeutics, Inc. (LENZ) And Encourages Shareholders to Reach Out - ACCESS Newswire

LENZ Therapeutics, Inc. (LENZ) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

LENZ Therapeutics, Inc. (LENZ) Investigation: Bronstein, Gewirtz - The National Law Review

LENZ Therapeutics: Still Speculative But Priced For Disasters (NASDAQ:LENZ) - Seeking Alpha

Lenz Therapeutics faces securities fraud probe after weak product sales and stock plunge. - pluang.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ - PR Newswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against LENZ Therapeutics, Inc. (LENZ) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ - financialcontent.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against LENZ Therapeutics, Inc. (LENZ) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against LENZ Therapeutics, Inc. (LENZ) And Encourages Investors to Reach Out - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against LENZ Therapeutics, Inc. (LENZ) And Encourages Stockholders to Reach Out - ACCESS Newswire

Blue Owl Capital Holdings LP Invests $4.30 Million in LENZ Therapeutics, Inc. $LENZ - MarketBeat

LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript - AOL.com

LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript - The Globe and Mail

LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript - The Globe and Mail

symbol__ Stock Quote Price and Forecast - CNN

LENZ Therapeutics (NASDAQ:LENZ) Stock Rating Upgraded by Zacks Research - MarketBeat

LENZ Therapeutics (LENZ) Stock Sees Fair Value Moves Lower After Analyst Target Cuts - Yahoo Finance

Q3 EPS Estimate for LENZ Therapeutics Increased by Analyst - MarketBeat

Earnings Release: Here's Why Analysts Cut Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target To US$26.83 - simplywall.st

Citi Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $10 - Moomoo

Lenz stock drops as Bank of America downgrades (LENZ:NASDAQ) - Seeking Alpha

A Quick Look at Today's Ratings for LENZ Therapeutics(LENZ.US), With a Forecast Between $7 to $38 - Moomoo

LENZ Therapeutics (LENZ) Stock Reflects Loss Fatigue Despite Long Cash Runway - Simply Wall Street

BofA Securities Downgrades LENZ Therapeutics(LENZ.US) to Hold Rating, Cuts Target Price to $7 - Moomoo

BofA downgrades Lenz Therapeutics stock rating on slow launch By Investing.com - Investing.com Australia

BofA downgrades Lenz Therapeutics stock rating on slow launch - Investing.com

BofA downgrades Lenz Therapeutics stock rating on slow launch By Investing.com - Investing.com South Africa

BofA downgrades Lenz Therapeutics stock rating on slow launch - Investing.com Nigeria

BofA downgrades Lenz Therapeutics stock rating on slow launch By Investing.com - Investing.com India

BofA downgrades Lenz Therapeutics stock rating on slow launch By Investing.com - Investing.com Canada

BofA downgrades Lenz Therapeutics stock rating on slow launch - Investing.com

Ähnlich wie LENZ

APMD$14.940.83%

DBVT$10.030.84%

AVBP$12.821.54%

GERN$0.99146.60%